<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05794243</url>
  </required_header>
  <id_info>
    <org_study_id>18360</org_study_id>
    <secondary_id>J1X-MC-GZHI</secondary_id>
    <nct_id>NCT05794243</nct_id>
  </id_info>
  <brief_title>A Multiple-Dose Study of LY3493269 in Healthy Participants</brief_title>
  <official_title>An Open-Label, Multiple-Dose Study to Investigate the Pharmacokinetics of LY3493269 Oral Formulations Administered in a Fed or Fasted State in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to conduct blood tests to measure how much LY3493269 is in&#xD;
      the bloodstream and how the body handles and eliminates LY3493269 when administered orally as&#xD;
      test compared to reference formulations in healthy participants in fed and/or fasted states.&#xD;
      The study will also evaluate the safety and tolerability of LY3493269 in these participants.&#xD;
      The study will last up to 43 days excluding the screening period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2023</start_date>
  <completion_date type="Anticipated">September 22, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 22, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration-time curve (AUC) of LY3493269</measure>
    <time_frame>Predose up to 43 days postdose</time_frame>
    <description>PK: AUC of LY3493269</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Maximum Observed Concentration (Cmax) of LY3493269</measure>
    <time_frame>Predose up to 43 days postdose</time_frame>
    <description>PK: Cmax of LY3493269</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3493269 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3493269 administered orally as test or reference formulations in participants who are in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3493269 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3493269 administered orally as test or reference formulations in participants who are either in a fasted or fed state.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3493269</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3493269 (Part A)</arm_group_label>
    <arm_group_label>LY3493269 (Part B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female participants who are overtly healthy as determined by medical&#xD;
             evaluation&#xD;
&#xD;
          -  Participants with body mass index (BMI) of 19.0 to 40.0 kilograms per meter squared&#xD;
             (kg/mÂ²)&#xD;
&#xD;
          -  Males who agree to use highly effective/effective methods of contraception and only&#xD;
             women not of child bearing potential may participate in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a history of atopy (severe or multiple allergic manifestations) or clinically&#xD;
             significant multiple or severe drug allergies, or intolerance to topical&#xD;
             corticosteroids, or severe posttreatment hypersensitivity reactions (including, but&#xD;
             not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic&#xD;
             epidermal necrolysis, anaphylaxis, angioedema, or exfoliative dermatitis)&#xD;
&#xD;
          -  Have a significant history of or current CV (for example, myocardial infarction,&#xD;
             congestive heart failure, cerebrovascular accident, venous thromboembolism, etc.),&#xD;
             respiratory, renal, GI (including involving the liver, gallbladder or gallbladder&#xD;
             surgery), endocrine, hematological (including history of thrombocytopenia), or&#xD;
             neurological disorders capable of significantly altering the absorption, metabolism,&#xD;
             or elimination of drugs; of constituting a risk while taking the IP; or of interfering&#xD;
             with the interpretation of data.&#xD;
&#xD;
          -  Have a mean supine HR less than 45 bpm or greater than 100 bpm from 2 assessments at&#xD;
             screening.&#xD;
&#xD;
          -  Have a mean supine systolic BP higher than 160 mmHg and a mean supine diastolic BP&#xD;
             higher than 95 mmHg from 2 assessments at screening&#xD;
&#xD;
          -  Have undergone any form of bariatric surgery.&#xD;
&#xD;
          -  Have a history of GI bleeding, or gastric or duodenal ulcers.&#xD;
&#xD;
          -  Have a personal or family history of medullary thyroid carcinoma or multiple endocrine&#xD;
             neoplasia syndrome type 2.&#xD;
&#xD;
          -  Have a history of acute or chronic pancreatitis, or elevation in serum lipase and/or&#xD;
             amylase levels greater than 1.5 times the ULN.&#xD;
&#xD;
          -  Have clinical signs or symptoms of liver disease, acute or chronic hepatitis.&#xD;
&#xD;
          -  Have evidence of significant active neuropsychiatric disease as determined by the&#xD;
             investigator.&#xD;
&#xD;
          -  Have been treated with prescription drugs that promote weight loss within 3 months&#xD;
             prior to screening.&#xD;
&#xD;
          -  Are currently enrolled in a clinical study involving an IP or any other type of&#xD;
             medical research judged not to be scientifically or medically compatible with this&#xD;
             study.&#xD;
&#xD;
          -  Have participated within the past 30 days of screening in a clinical study involving&#xD;
             an IP; at least 5 half-lives or 30 days, whichever is longer, should have passed.&#xD;
&#xD;
          -  Have an abnormality in the 12-lead ECG at screening that, in the opinion of the&#xD;
             investigator, increases the risks associated with participating in the study or may&#xD;
             confound ECG (QT) data analysis, such as a QTcF &gt;450 msec for males and &gt;470 msec for&#xD;
             females, short PR interval (&lt;120 msec), or PR interval &gt;220 msec, second- or&#xD;
             third-degree atrioventricular block, intraventricular conduction delay with QRS &gt;120&#xD;
             msec, right bundle branch block, left bundle branch block or Wolff-Parkinson-White&#xD;
             syndrome.&#xD;
&#xD;
          -  Have serum AST or ALT &gt;1.5x ULN or TBL &gt;1.5x ULN.&#xD;
&#xD;
          -  Show evidence of human immunodeficiency virus infection and/or positive human&#xD;
             immunodeficiency virus antibodies.&#xD;
&#xD;
          -  Show evidence of hepatitis C and/or positive hepatitis C antibody.&#xD;
&#xD;
          -  Show evidence of hepatitis B, positive hepatitis B core antibody, and/or positive&#xD;
             hepatitis B surface antigen.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@Lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lilly Centre for Clinical Pharmacology</name>
      <address>
        <city>Singapore</city>
        <zip>138623</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>64139811</phone>
    </contact>
    <investigator>
      <last_name>Jennifer Lua</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>April 1, 2023</verification_date>
  <study_first_submitted>March 21, 2023</study_first_submitted>
  <study_first_submitted_qc>March 21, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>April 13, 2023</last_update_submitted>
  <last_update_submitted_qc>April 13, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

